Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
HONG KONG and PETAH TIKVA, Israel, Nov. 23, 2015 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ:GILT) (TASE:GILT), a worldwide leader in satellite networking technology, solutions and...
-
PETAH TIKVA, Israel, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ:GILT) (TASE:GILT), a worldwide leader in satellite networking technology, solutions and services,...
-
REHOVOT, Israel, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries,...
-
QUARTERLY GROWTH OF 11.3% IN REVENUES TO USD 234.5M AND 15.9% IN EBITDA TO USD 45.2M; HIGHEST EVER IN COMPANY HISTORY NET INCOME (ADJUSTED FOR NON-RECURRING EXPENSES1 AND ON A...
-
PETAH TIKVA, Israel, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ:GILT) (TASE:GILT), a worldwide leader in satellite networking technology, solutions and services, today...
-
NEW YORK, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Medley Management Inc. (NYSE:MDLY) announced today that it has changed the record date for its upcoming dividend from November 25, 2015 to November 27,...
-
NETANYA, Israel, Nov. 17, 2015 (GLOBE NEWSWIRE) -- RADA Electronic Industries Ltd. (NASDAQ:RADA) today announced its financial results for the third quarter and the nine months ended...
-
PETAH TIKVA, Israel, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ:GILT) (TASE:GILT), a worldwide leader in satellite networking technology, solutions and services, today...
-
HAIFA, Israel, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that Dr....
-
Clear Path for Biologics License Application (BLA) Submission One Short-Term Safety and Efficacy Study Required to Support Full Approval In Parallel, Protalix to Conduct Phase III Head-to-Head...